Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Rowland

Showing results (151-160 of 184) with videos related to

Pageof 19
Sort By:
British Journal of Clinical Pharmacology|December 2, 2017
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulationThomas M Polasek, Geoffrey T Tucker, Michael J Sorich, et al.
Pharmaceutics|January 21, 2022
Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine ExposureKenneth H Wills, Stephen J Behan, Michael J Nance, et al.
International Journal of Cancer|March 13, 2025
Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trialYuan Gao, Ann-Lii Cheng, Lee X Li, et al.
British Journal of Cancer|October 29, 2021
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150Ashley M Hopkins, Ganessan Kichenadasse, Ross A McKinnon, et al.
Epidemiology (Cambridge, Mass.)|January 24, 2002
Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from IowaAaron Blair, Robert Tarone, Dale Sandler, et al.
BMC Cancer|March 26, 2024
A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trialsLee X Li, Mark A Socinski, Ganessan Kichenadasse, et al.
Frontiers in Oncology|August 8, 2020
The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial DataNatansh D Modi, Jin Quan Eugene Tan, Andrew Rowland, et al.
JNCI Cancer Spectrum|January 8, 2026
Heterogeneous Treatment Effect of Immune Checkpoint inhibitors by Pre-treatment Prognosis in Randomised Controlled TrialsLee X Li, Adel Shahnam, Ganessan Kichenadasse, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|August 30, 2005
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of methylphenidateMari Golub, Lucio Costa, Kevin Crofton, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|September 17, 2005
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamineMari Golub, Lucio Costa, Kevin Crofton, et al.
Pageof 19

Showing results (151-160 of 184) with videos related to

Sort By:
Pageof 19
British Journal of Clinical Pharmacology|December 2, 2017
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulationThomas M Polasek, Geoffrey T Tucker, Michael J Sorich, et al.
Pharmaceutics|January 21, 2022
Combining Therapeutic Drug Monitoring and Pharmacokinetic Modelling Deconvolutes Physiological and Environmental Sources of Variability in Clozapine ExposureKenneth H Wills, Stephen J Behan, Michael J Nance, et al.
International Journal of Cancer|March 13, 2025
Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trialYuan Gao, Ann-Lii Cheng, Lee X Li, et al.
British Journal of Cancer|October 29, 2021
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150Ashley M Hopkins, Ganessan Kichenadasse, Ross A McKinnon, et al.
Epidemiology (Cambridge, Mass.)|January 24, 2002
Reliability of reporting on life-style and agricultural factors by a sample of participants in the Agricultural Health Study from IowaAaron Blair, Robert Tarone, Dale Sandler, et al.
BMC Cancer|March 26, 2024
A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trialsLee X Li, Mark A Socinski, Ganessan Kichenadasse, et al.
Frontiers in Oncology|August 8, 2020
The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial DataNatansh D Modi, Jin Quan Eugene Tan, Andrew Rowland, et al.
JNCI Cancer Spectrum|January 8, 2026
Heterogeneous Treatment Effect of Immune Checkpoint inhibitors by Pre-treatment Prognosis in Randomised Controlled TrialsLee X Li, Adel Shahnam, Ganessan Kichenadasse, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|August 30, 2005
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of methylphenidateMari Golub, Lucio Costa, Kevin Crofton, et al.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|September 17, 2005
NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of amphetamine and methamphetamineMari Golub, Lucio Costa, Kevin Crofton, et al.
Pageof 19